Cargando…

474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management

BACKGROUND: Although skin and soft-tissue infections (SSTIs) remain a common cause of hospitalization for intravenous drug users (IVDU), little has been done to identify whether there should be differences in the SSTI management of IVDU vs. nonusers. The objective of this study was to evaluate the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivey, Alison, Holt, Shannon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809878/
http://dx.doi.org/10.1093/ofid/ofz360.547
_version_ 1783462105351979008
author Ivey, Alison
Holt, Shannon
author_facet Ivey, Alison
Holt, Shannon
author_sort Ivey, Alison
collection PubMed
description BACKGROUND: Although skin and soft-tissue infections (SSTIs) remain a common cause of hospitalization for intravenous drug users (IVDU), little has been done to identify whether there should be differences in the SSTI management of IVDU vs. nonusers. The objective of this study was to evaluate the impact of documented intravenous drug abuse on the overall management of invasive SSTIs in hospitalized patients. METHODS: This retrospective cohort study randomly selected 100 IVDU and 100 nonusers (controls) hospitalized for an SSTI over 18 months in a community teaching hospital. Patients eligible for inclusion were 18–60 years old and treated with IV inpatient antibiotics for at least 48 hours. Pregnant women, transfers from an outside hospital, and diabetic foot infections were excluded. The primary endpoint was hospital length of stay (LOS). Secondary endpoints included: percentage prescribed empiric combination antibiotic therapy, percentage prescribed an anti-pseudomonal agent, inpatient and total antibiotic duration of therapy (DOT), 30-day readmission rates, and 30-day emergency department (ED) visit rates. RESULTS: The study population was predominantly male (66%), Caucasian (72%), and had a mean age of 40 years old (18–59). IVDU were more likely to have complications (18% vs. 6%) and polymicrobial infections (19% vs. 2%), Mean hospital length of stay was 9.0 days for IVDU compared with 4.8 days for controls (P < 0.001). There was no difference in empiric combination therapy (48% vs. 37%; P = 0.115) or empiric exposure to an anti-pseudomonal agent (38% vs. 30%; P = 0.232). Mean duration of inpatient antibiotic DOT was longer in IVDU (7.5 days vs. 4.3 days; P < 0.001), but total antibiotic DOT was similar between groups (16.0 days vs. 13.8 days; P = 0.141). Thirty-day ED visits were higher for IVDU (16% vs. 5%; P = 0.009); however, there was no difference in 30-day readmission (14% vs. 16%; P = 0.692). CONCLUSION: Documented IV drug abuse resulted in a significant increase in the length of stay in hospitalized adults with SSTIs requiring IV antibiotics. Exposure to combination therapy and anti-pseudomonal agents did not differ between the groups as would be expected. In the future stewardship initiatives are needed to increase adherence to SSTI guideline recommendations for empiric therapy. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809878
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68098782019-10-28 474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management Ivey, Alison Holt, Shannon Open Forum Infect Dis Abstracts BACKGROUND: Although skin and soft-tissue infections (SSTIs) remain a common cause of hospitalization for intravenous drug users (IVDU), little has been done to identify whether there should be differences in the SSTI management of IVDU vs. nonusers. The objective of this study was to evaluate the impact of documented intravenous drug abuse on the overall management of invasive SSTIs in hospitalized patients. METHODS: This retrospective cohort study randomly selected 100 IVDU and 100 nonusers (controls) hospitalized for an SSTI over 18 months in a community teaching hospital. Patients eligible for inclusion were 18–60 years old and treated with IV inpatient antibiotics for at least 48 hours. Pregnant women, transfers from an outside hospital, and diabetic foot infections were excluded. The primary endpoint was hospital length of stay (LOS). Secondary endpoints included: percentage prescribed empiric combination antibiotic therapy, percentage prescribed an anti-pseudomonal agent, inpatient and total antibiotic duration of therapy (DOT), 30-day readmission rates, and 30-day emergency department (ED) visit rates. RESULTS: The study population was predominantly male (66%), Caucasian (72%), and had a mean age of 40 years old (18–59). IVDU were more likely to have complications (18% vs. 6%) and polymicrobial infections (19% vs. 2%), Mean hospital length of stay was 9.0 days for IVDU compared with 4.8 days for controls (P < 0.001). There was no difference in empiric combination therapy (48% vs. 37%; P = 0.115) or empiric exposure to an anti-pseudomonal agent (38% vs. 30%; P = 0.232). Mean duration of inpatient antibiotic DOT was longer in IVDU (7.5 days vs. 4.3 days; P < 0.001), but total antibiotic DOT was similar between groups (16.0 days vs. 13.8 days; P = 0.141). Thirty-day ED visits were higher for IVDU (16% vs. 5%; P = 0.009); however, there was no difference in 30-day readmission (14% vs. 16%; P = 0.692). CONCLUSION: Documented IV drug abuse resulted in a significant increase in the length of stay in hospitalized adults with SSTIs requiring IV antibiotics. Exposure to combination therapy and anti-pseudomonal agents did not differ between the groups as would be expected. In the future stewardship initiatives are needed to increase adherence to SSTI guideline recommendations for empiric therapy. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809878/ http://dx.doi.org/10.1093/ofid/ofz360.547 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ivey, Alison
Holt, Shannon
474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management
title 474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management
title_full 474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management
title_fullStr 474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management
title_full_unstemmed 474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management
title_short 474. Battling Addiction: Impact of Intravenous Drug Use on Invasive Skin and Soft Tissue Management
title_sort 474. battling addiction: impact of intravenous drug use on invasive skin and soft tissue management
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809878/
http://dx.doi.org/10.1093/ofid/ofz360.547
work_keys_str_mv AT iveyalison 474battlingaddictionimpactofintravenousdruguseoninvasiveskinandsofttissuemanagement
AT holtshannon 474battlingaddictionimpactofintravenousdruguseoninvasiveskinandsofttissuemanagement